Overview
Thin endometrium, often referred to as thin attached gingiva in the context of reproductive health, is a condition characterized by reduced endometrial thickness, typically defined as less than 7-8 mm in the secretory phase. This condition can significantly impact fertility by impairing implantation due to inadequate uterine receptivity. The pathophysiology of thin endometrium involves complex interactions between cellular components and extracellular matrix, with emerging evidence highlighting the critical role of specific cell populations such as CD9+SUSD2+ cells. Understanding these cellular dynamics is crucial for both diagnosing and potentially managing this condition effectively.
Pathophysiology
The endometrium's structural integrity and functional capacity are maintained by a delicate balance of cellular activities, particularly during the menstrual cycle phases. Recent advances in single-cell RNA sequencing have illuminated the importance of CD9+SUSD2+ cells in this process [PMID:41013639]. These cells are predominantly active during the proliferative phase, contributing significantly to the healthy development and maintenance of the endometrium. Studies have shown that CD9+SUSD2+ cells are more abundant in healthy endometrium compared to the secretory phase, indicating their pivotal role in the proliferative phase's regenerative processes [PMID:41013639]. Disruptions in the collagen deposition around blood vessels, often involving these cells, have been observed in conditions such as thin endometrium (TE), underscoring their critical function in maintaining endometrial thickness and structural integrity [PMID:41013639]. This dysregulation can lead to compromised endometrial receptivity, a key factor in implantation failure and recurrent pregnancy loss.
In clinical practice, the identification of altered CD9+SUSD2+ cell populations may serve as a biomarker for assessing endometrial health. The functional impairment of these cells suggests that interventions aimed at restoring their normal function could be beneficial in managing thin endometrium. However, further research is needed to fully elucidate the mechanisms underlying these cellular disruptions and their broader implications on endometrial physiology.
Diagnosis
Diagnosing thin endometrium traditionally relies on imaging techniques such as transvaginal ultrasound, which measures endometrial thickness. However, the recent focus on cellular markers offers a more nuanced approach to diagnosis. Specifically, assessing the abundance and function of CD9+SUSD2+ cells via immunofluorescence techniques may provide additional diagnostic value [PMID:41013639]. These cells, when present in lower numbers or exhibiting altered functional profiles, can indicate compromised endometrial health indicative of thin endometrium.
In clinical settings, combining traditional ultrasound measurements with immunohistochemical assessments of CD9+SUSD2+ cells could enhance diagnostic accuracy. This dual approach not only confirms the thickness but also provides insights into the underlying cellular dysfunction. However, the widespread adoption of these advanced diagnostic methods remains limited due to the need for specialized laboratory capabilities and standardized protocols. Therefore, while promising, these techniques are currently considered adjunctive rather than primary diagnostic tools in routine clinical practice.
Management
The management of thin endometrium often involves a multifaceted approach aimed at improving endometrial thickness and receptivity. Given the identified critical role of CD9+SUSD2+ cells in endometrial repair and maintenance, future therapeutic strategies may focus on enhancing their function or abundance [PMID:41013639]. Potential interventions could include:
In clinical practice, individualized treatment plans are essential, considering factors such as patient age, underlying causes of thin endometrium, and reproductive history. While these cellular-focused approaches hold promise, their efficacy and safety profiles require rigorous clinical trials for validation. Currently, the mainstay of management continues to rely on empirical hormonal therapies, with ongoing research exploring more targeted cellular interventions.
Key Recommendations
These recommendations aim to integrate current evidence with clinical practice, emphasizing the evolving understanding of endometrial cellular dynamics in managing thin endometrium effectively.
References
1 Liang B, Qi L, Chen M, Mai C, Diao L, Ding L et al.. Single-cell RNA sequencing of endometrium uncovers dynamic characteristics and dysregulation of perivascular CD9+SUSD2+ cells in thin endometrium. Stem cell research & therapy 2025. link
1 papers cited of 3 indexed.